#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The Flavivirus genus of the family Flaviviridae includes several arthropod-borne human pathogens that may cause a spectrum of clinical syndromes ranging from a mild febrile illness to severe hemorrhagic fever or neuroinvasive disease .
2-1	16-19	The	abstract[3]	new[3]	_	_
2-2	20-30	Flavivirus	plant|abstract[3]	new|new[3]	coref	16-20
2-3	31-36	genus	abstract[3]	new[3]	_	_
2-4	37-39	of	abstract[3]	new[3]	_	_
2-5	40-43	the	abstract[3]|animal[5]	new[3]|new[5]	_	_
2-6	44-50	family	abstract[3]|person|animal[5]	new[3]|new|new[5]	_	_
2-7	51-63	Flaviviridae	abstract[3]|animal[5]	new[3]|new[5]	_	_
2-8	64-72	includes	_	_	_	_
2-9	73-80	several	abstract[6]	new[6]	_	_
2-10	81-96	arthropod-borne	abstract[6]	new[6]	_	_
2-11	97-102	human	abstract[6]	new[6]	_	_
2-12	103-112	pathogens	abstract[6]	new[6]	_	_
2-13	113-117	that	_	_	_	_
2-14	118-121	may	_	_	_	_
2-15	122-127	cause	_	_	_	_
2-16	128-129	a	abstract[7]	new[7]	_	_
2-17	130-138	spectrum	abstract[7]	new[7]	_	_
2-18	139-141	of	abstract[7]	new[7]	_	_
2-19	142-150	clinical	abstract[7]|abstract[8]	new[7]|new[8]	coref	12-16[99_8]
2-20	151-160	syndromes	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-21	161-168	ranging	_	_	_	_
2-22	169-173	from	_	_	_	_
2-23	174-175	a	abstract[10]	new[10]	coref	4-9[37_10]
2-24	176-180	mild	abstract[10]	new[10]	_	_
2-25	181-188	febrile	object|abstract[10]	new|new[10]	coref	6-13
2-26	189-196	illness	abstract[10]	new[10]	_	_
2-27	197-199	to	abstract[10]	new[10]	_	_
2-28	200-206	severe	abstract[10]|abstract[12]	new[10]|new[12]	coref	11-34[0_12]
2-29	207-218	hemorrhagic	abstract[10]|place|abstract[12]	new[10]|new|new[12]	coref	11-45
2-30	219-224	fever	abstract[10]|abstract[12]	new[10]|new[12]	_	_
2-31	225-227	or	abstract[10]	new[10]	_	_
2-32	228-241	neuroinvasive	abstract[10]|abstract[13]	new[10]|new[13]	coref	4-13[38_13]
2-33	242-249	disease	abstract[10]|abstract[13]	new[10]|new[13]	_	_
2-34	250-251	.	_	_	_	_

#Text=Neurotropic flaviviruses , such as West Nile virus ( WNV ) , Japanese encephalitis virus ( JEV ) , and tick-borne encephalitis virus ( TBEV ) , are maintained in nature in transmission cycles involving mosquito ( mainly Culex spp. ) or tick ( mainly Ixodes spp. ) vectors and mammalian or bird amplification hosts , with humans serving as dead-end incidental hosts .
3-1	252-263	Neurotropic	abstract|object[15]	new|new[15]	coref|coref|coref|coref	6-2[49_15]|11-6|6-2[49_15]|11-6
3-2	264-276	flaviviruses	object[15]	new[15]	_	_
3-3	277-278	,	object[15]	new[15]	_	_
3-4	279-283	such	object[15]	new[15]	_	_
3-5	284-286	as	object[15]	new[15]	_	_
3-6	287-291	West	object[15]|place[16]|abstract[17]	new[15]|new[16]|new[17]	appos|appos	3-10[0_17]|3-10[0_17]
3-7	292-296	Nile	object[15]|place[16]|abstract[17]	new[15]|new[16]|new[17]	_	_
3-8	297-302	virus	object[15]|abstract[17]	new[15]|new[17]	_	_
3-9	303-304	(	_	_	_	_
3-10	305-308	WNV	abstract	giv	coref	21-39
3-11	309-310	)	_	_	_	_
3-12	311-312	,	_	_	_	_
3-13	313-321	Japanese	abstract[20]	new[20]	appos	3-17[0_20]
3-14	322-334	encephalitis	abstract|abstract[20]	new|new[20]	coref	3-22
3-15	335-340	virus	abstract[20]	new[20]	_	_
3-16	341-342	(	_	_	_	_
3-17	343-346	JEV	abstract	giv	_	_
3-18	347-348	)	_	_	_	_
3-19	349-350	,	_	_	_	_
3-20	351-354	and	_	_	_	_
3-21	355-365	tick-borne	abstract[23]	new[23]	appos	3-25[0_23]
3-22	366-378	encephalitis	abstract|abstract[23]	giv|new[23]	_	_
3-23	379-384	virus	abstract[23]	new[23]	_	_
3-24	385-386	(	_	_	_	_
3-25	387-391	TBEV	abstract	giv	coref	5-1[43_0]
3-26	392-393	)	_	_	_	_
3-27	394-395	,	_	_	_	_
3-28	396-399	are	_	_	_	_
3-29	400-410	maintained	_	_	_	_
3-30	411-413	in	_	_	_	_
3-31	414-420	nature	abstract[25]	new[25]	_	_
3-32	421-423	in	abstract[25]	new[25]	_	_
3-33	424-436	transmission	abstract[25]|abstract|abstract[27]	new[25]|new|new[27]	_	_
3-34	437-443	cycles	abstract[25]|abstract[27]	new[25]|new[27]	_	_
3-35	444-453	involving	_	_	_	_
3-36	454-462	mosquito	animal	new	_	_
3-37	463-464	(	_	_	_	_
3-38	465-471	mainly	_	_	_	_
3-39	472-477	Culex	_	_	_	_
3-40	478-482	spp.	_	_	_	_
3-41	483-484	)	_	_	_	_
3-42	485-487	or	_	_	_	_
3-43	488-492	tick	person	new	_	_
3-44	493-494	(	_	_	_	_
3-45	495-501	mainly	_	_	_	_
3-46	502-508	Ixodes	person	new	_	_
3-47	509-513	spp.	_	_	_	_
3-48	514-515	)	_	_	_	_
3-49	516-523	vectors	person	new	_	_
3-50	524-527	and	_	_	_	_
3-51	528-537	mammalian	person	new	_	_
3-52	538-540	or	_	_	_	_
3-53	541-545	bird	animal|person[34]	new|new[34]	_	_
3-54	546-559	amplification	person[34]	new[34]	_	_
3-55	560-565	hosts	person[34]	new[34]	_	_
3-56	566-567	,	_	_	_	_
3-57	568-572	with	_	_	_	_
3-58	573-579	humans	person	new	coref	9-5[69_0]
3-59	580-587	serving	_	_	_	_
3-60	588-590	as	_	_	_	_
3-61	591-599	dead-end	_	_	_	_
3-62	600-610	incidental	_	_	_	_
3-63	611-616	hosts	_	_	_	_
3-64	617-618	.	_	_	_	_

#Text=Most human infections are asymptomatic or characterized by flu-like illness , while a severe and potentially fatal neuroinvasive disease occurs in a minority of cases , mostly immunocompromised and elderly individuals .
4-1	619-623	Most	abstract[36]	new[36]	coref	6-8[51_36]
4-2	624-629	human	abstract[36]	new[36]	_	_
4-3	630-640	infections	abstract[36]	new[36]	_	_
4-4	641-644	are	_	_	_	_
4-5	645-657	asymptomatic	_	_	_	_
4-6	658-660	or	_	_	_	_
4-7	661-674	characterized	_	_	_	_
4-8	675-677	by	_	_	_	_
4-9	678-686	flu-like	abstract[37]	giv[37]	coref	6-11[53_37]
4-10	687-694	illness	abstract[37]	giv[37]	_	_
4-11	695-696	,	_	_	_	_
4-12	697-702	while	_	_	_	_
4-13	703-704	a	abstract[38]	giv[38]	coref	11-45[93_38]
4-14	705-711	severe	abstract[38]	giv[38]	_	_
4-15	712-715	and	abstract[38]	giv[38]	_	_
4-16	716-727	potentially	abstract[38]	giv[38]	_	_
4-17	728-733	fatal	abstract[38]	giv[38]	_	_
4-18	734-747	neuroinvasive	abstract[38]	giv[38]	_	_
4-19	748-755	disease	abstract[38]	giv[38]	_	_
4-20	756-762	occurs	_	_	_	_
4-21	763-765	in	_	_	_	_
4-22	766-767	a	quantity[39]	new[39]	_	_
4-23	768-776	minority	quantity[39]	new[39]	_	_
4-24	777-779	of	quantity[39]	new[39]	_	_
4-25	780-785	cases	quantity[39]|abstract	new[39]|new	coref	11-16[83_0]
4-26	786-787	,	_	_	_	_
4-27	788-794	mostly	_	_	_	_
4-28	795-812	immunocompromised	_	_	_	_
4-29	813-816	and	_	_	_	_
4-30	817-824	elderly	_	_	_	_
4-31	825-836	individuals	person	new	coref	8-14[67_0]
4-32	837-838	.	_	_	_	_

#Text=Zika virus ( ZIKV ) has recently drawn attention due to the large outbreaks that occurred in Pacific Ocean countries and the Americas .
5-1	839-843	Zika	object|abstract[43]	new|giv[43]	appos|coref|appos|coref	5-4[0_43]|7-22|5-4[0_43]|7-22
5-2	844-849	virus	abstract[43]	giv[43]	_	_
5-3	850-851	(	_	_	_	_
5-4	852-856	ZIKV	abstract	giv	coref	6-5
5-5	857-858	)	_	_	_	_
5-6	859-862	has	_	_	_	_
5-7	863-871	recently	_	_	_	_
5-8	872-877	drawn	_	_	_	_
5-9	878-887	attention	abstract	new	_	_
5-10	888-891	due	_	_	_	_
5-11	892-894	to	_	_	_	_
5-12	895-898	the	event[46]	new[46]	_	_
5-13	899-904	large	event[46]	new[46]	_	_
5-14	905-914	outbreaks	event[46]	new[46]	_	_
5-15	915-919	that	_	_	_	_
5-16	920-928	occurred	_	_	_	_
5-17	929-931	in	_	_	_	_
5-18	932-939	Pacific	place[47]	new[47]	_	_
5-19	940-945	Ocean	place[47]	new[47]	_	_
5-20	946-955	countries	place[47]	new[47]	_	_
5-21	956-959	and	_	_	_	_
5-22	960-963	the	place[48]	new[48]	_	_
5-23	964-972	Americas	place[48]	new[48]	_	_
5-24	973-974	.	_	_	_	_

#Text=Like other flaviviruses , ZIKV generally causes asymptomatic infections or a mild febrile illness .
6-1	975-979	Like	_	_	_	_
6-2	980-985	other	object[49]	giv[49]	coref	10-3[0_49]
6-3	986-998	flaviviruses	object[49]	giv[49]	_	_
6-4	999-1000	,	_	_	_	_
6-5	1001-1005	ZIKV	object	giv	coref	7-23
6-6	1006-1015	generally	_	_	_	_
6-7	1016-1022	causes	_	_	_	_
6-8	1023-1035	asymptomatic	abstract[51]	giv[51]	coref	12-21[100_51]
6-9	1036-1046	infections	abstract[51]	giv[51]	_	_
6-10	1047-1049	or	abstract[51]	giv[51]	_	_
6-11	1050-1051	a	abstract[51]|abstract[53]	giv[51]|giv[53]	_	_
6-12	1052-1056	mild	abstract[51]|abstract[53]	giv[51]|giv[53]	_	_
6-13	1057-1064	febrile	abstract[51]|object|abstract[53]	giv[51]|giv|giv[53]	_	_
6-14	1065-1072	illness	abstract[51]|abstract[53]	giv[51]|giv[53]	_	_
6-15	1073-1074	.	_	_	_	_

#Text=Infection during pregnancy , especially during the first trimester , causes fetal microcephaly and other developmental anomalies , defined as congenital Zika virus syndrome .
7-1	1075-1084	Infection	abstract[54]	new[54]	coref	8-11[66_54]
7-2	1085-1091	during	abstract[54]	new[54]	_	_
7-3	1092-1101	pregnancy	abstract[54]|event	new[54]|new	_	_
7-4	1102-1103	,	_	_	_	_
7-5	1104-1114	especially	abstract[56]	new[56]	_	_
7-6	1115-1121	during	abstract[56]	new[56]	_	_
7-7	1122-1125	the	abstract[56]	new[56]	_	_
7-8	1126-1131	first	abstract[56]	new[56]	_	_
7-9	1132-1141	trimester	abstract[56]	new[56]	_	_
7-10	1142-1143	,	_	_	_	_
7-11	1144-1150	causes	_	_	_	_
7-12	1151-1156	fetal	_	_	_	_
7-13	1157-1169	microcephaly	_	_	_	_
7-14	1170-1173	and	_	_	_	_
7-15	1174-1179	other	abstract[57]	new[57]	_	_
7-16	1180-1193	developmental	abstract[57]	new[57]	_	_
7-17	1194-1203	anomalies	abstract[57]	new[57]	_	_
7-18	1204-1205	,	_	_	_	_
7-19	1206-1213	defined	_	_	_	_
7-20	1214-1216	as	_	_	_	_
7-21	1217-1227	congenital	_	_	_	_
7-22	1228-1232	Zika	place	giv	_	_
7-23	1233-1238	virus	abstract	giv	coref	8-11
7-24	1239-1247	syndrome	_	_	_	_
7-25	1248-1249	.	_	_	_	_

#Text=Guillain – Barré syndrome and meningoencephalitis are rare complications of ZIKV infection in adult individuals .
8-1	1250-1258	Guillain	person	new	_	_
8-2	1259-1260	–	_	_	_	_
8-3	1261-1266	Barré	person|abstract[62]	new|new[62]	_	_
8-4	1267-1275	syndrome	abstract[62]	new[62]	_	_
8-5	1276-1279	and	_	_	_	_
8-6	1280-1299	meningoencephalitis	abstract	new	coref	8-8[64_0]
8-7	1300-1303	are	_	_	_	_
8-8	1304-1308	rare	abstract[64]	giv[64]	coref	11-19[84_64]
8-9	1309-1322	complications	abstract[64]	giv[64]	_	_
8-10	1323-1325	of	abstract[64]	giv[64]	_	_
8-11	1326-1330	ZIKV	abstract[64]|object|abstract[66]	giv[64]|giv|giv[66]	coref|coref|coref|coref	9-1|12-32[0_66]|9-1|12-32[0_66]
8-12	1331-1340	infection	abstract[64]|abstract[66]	giv[64]|giv[66]	_	_
8-13	1341-1343	in	abstract[64]|abstract[66]	giv[64]|giv[66]	_	_
8-14	1344-1349	adult	abstract[64]|abstract[66]|person[67]	giv[64]|giv[66]|giv[67]	_	_
8-15	1350-1361	individuals	abstract[64]|abstract[66]|person[67]	giv[64]|giv[66]|giv[67]	_	_
8-16	1362-1363	.	_	_	_	_

#Text=ZIKV is transmitted between humans through the bite of infected Ae . aegypti and other Aedes species mosquitoes , with humans serving as amplifying hosts .
9-1	1364-1368	ZIKV	object	giv	coref	10-5
9-2	1369-1371	is	_	_	_	_
9-3	1372-1383	transmitted	_	_	_	_
9-4	1384-1391	between	_	_	_	_
9-5	1392-1398	humans	person[69]	giv[69]	coref	9-21[0_69]
9-6	1399-1406	through	person[69]	giv[69]	_	_
9-7	1407-1410	the	person[69]|abstract[70]	giv[69]|new[70]	_	_
9-8	1411-1415	bite	person[69]|abstract[70]	giv[69]|new[70]	_	_
9-9	1416-1418	of	person[69]|abstract[70]	giv[69]|new[70]	_	_
9-10	1419-1427	infected	person[69]|abstract[70]|person[71]	giv[69]|new[70]|new[71]	_	_
9-11	1428-1430	Ae	person[69]|abstract[70]|person[71]	giv[69]|new[70]|new[71]	_	_
9-12	1431-1432	.	person[69]|abstract[70]	giv[69]|new[70]	_	_
9-13	1433-1440	aegypti	person[69]|abstract[70]	giv[69]|new[70]	_	_
9-14	1441-1444	and	person[69]|abstract[70]	giv[69]|new[70]	_	_
9-15	1445-1450	other	person[69]|abstract[70]|animal[74]	giv[69]|new[70]|new[74]	_	_
9-16	1451-1456	Aedes	person[69]|abstract[70]|animal|animal[74]	giv[69]|new[70]|new|new[74]	_	_
9-17	1457-1464	species	person[69]|abstract[70]|animal|animal[74]	giv[69]|new[70]|new|new[74]	_	_
9-18	1465-1475	mosquitoes	person[69]|abstract[70]|animal[74]	giv[69]|new[70]|new[74]	_	_
9-19	1476-1477	,	_	_	_	_
9-20	1478-1482	with	_	_	_	_
9-21	1483-1489	humans	person	giv	coref	26-31
9-22	1490-1497	serving	_	_	_	_
9-23	1498-1500	as	_	_	_	_
9-24	1501-1511	amplifying	_	_	_	_
9-25	1512-1517	hosts	_	_	_	_
9-26	1518-1519	.	_	_	_	_

#Text=Unique among flaviviruses , ZIKV can persist in immune-privileged sites like the testis and be sexually transmitted .
10-1	1520-1526	Unique	_	_	_	_
10-2	1527-1532	among	_	_	_	_
10-3	1533-1545	flaviviruses	object	giv	coref	11-4[81_0]
10-4	1546-1547	,	_	_	_	_
10-5	1548-1552	ZIKV	object	giv	coref	11-27[87_0]
10-6	1553-1556	can	_	_	_	_
10-7	1557-1564	persist	_	_	_	_
10-8	1565-1567	in	_	_	_	_
10-9	1568-1585	immune-privileged	place[78]	new[78]	_	_
10-10	1586-1591	sites	place[78]	new[78]	_	_
10-11	1592-1596	like	place[78]	new[78]	_	_
10-12	1597-1600	the	place[78]|object[79]	new[78]|new[79]	_	_
10-13	1601-1607	testis	place[78]|object[79]	new[78]|new[79]	_	_
10-14	1608-1611	and	_	_	_	_
10-15	1612-1614	be	_	_	_	_
10-16	1615-1623	sexually	_	_	_	_
10-17	1624-1635	transmitted	_	_	_	_
10-18	1636-1637	.	_	_	_	_

#Text=In addition to these well-known neurotropic flaviviruses , there has been an increasing number of reported cases of neurological complications caused by viruses , such as dengue virus ( DENV ) and yellow fever virus ( YFV ) , which usually are associated with hemorrhagic disease .
11-1	1638-1640	In	_	_	_	_
11-2	1641-1649	addition	_	_	_	_
11-3	1650-1652	to	_	_	_	_
11-4	1653-1658	these	object[81]	giv[81]	coref	21-3[224_81]
11-5	1659-1669	well-known	object[81]	giv[81]	_	_
11-6	1670-1681	neurotropic	abstract|object[81]	giv|giv[81]	coref	21-36
11-7	1682-1694	flaviviruses	object[81]	giv[81]	_	_
11-8	1695-1696	,	_	_	_	_
11-9	1697-1702	there	_	_	_	_
11-10	1703-1706	has	_	_	_	_
11-11	1707-1711	been	_	_	_	_
11-12	1712-1714	an	abstract[82]	new[82]	_	_
11-13	1715-1725	increasing	abstract[82]	new[82]	_	_
11-14	1726-1732	number	abstract[82]	new[82]	_	_
11-15	1733-1735	of	abstract[82]	new[82]	_	_
11-16	1736-1744	reported	abstract[82]|abstract[83]	new[82]|giv[83]	_	_
11-17	1745-1750	cases	abstract[82]|abstract[83]	new[82]|giv[83]	_	_
11-18	1751-1753	of	abstract[82]|abstract[83]	new[82]|giv[83]	_	_
11-19	1754-1766	neurological	abstract[82]|abstract[83]|abstract[84]	new[82]|giv[83]|giv[84]	_	_
11-20	1767-1780	complications	abstract[82]|abstract[83]|abstract[84]	new[82]|giv[83]|giv[84]	_	_
11-21	1781-1787	caused	_	_	_	_
11-22	1788-1790	by	_	_	_	_
11-23	1791-1798	viruses	object[85]	new[85]	coref	20-7[0_85]
11-24	1799-1800	,	object[85]	new[85]	_	_
11-25	1801-1805	such	object[85]	new[85]	_	_
11-26	1806-1808	as	object[85]	new[85]	_	_
11-27	1809-1815	dengue	object[85]|object|abstract[87]	new[85]|new|giv[87]	appos|appos	11-30[0_87]|11-30[0_87]
11-28	1816-1821	virus	object[85]|abstract[87]	new[85]|giv[87]	_	_
11-29	1822-1823	(	_	_	_	_
11-30	1824-1828	DENV	abstract	giv	coref	11-33[90_0]
11-31	1829-1830	)	_	_	_	_
11-32	1831-1834	and	_	_	_	_
11-33	1835-1841	yellow	abstract[90]	giv[90]	appos	11-37[0_90]
11-34	1842-1847	fever	abstract|abstract[90]	giv|giv[90]	_	_
11-35	1848-1853	virus	abstract[90]	giv[90]	_	_
11-36	1854-1855	(	_	_	_	_
11-37	1856-1859	YFV	abstract	giv	coref	13-12
11-38	1860-1861	)	_	_	_	_
11-39	1862-1863	,	_	_	_	_
11-40	1864-1869	which	_	_	_	_
11-41	1870-1877	usually	_	_	_	_
11-42	1878-1881	are	_	_	_	_
11-43	1882-1892	associated	_	_	_	_
11-44	1893-1897	with	_	_	_	_
11-45	1898-1909	hemorrhagic	place|abstract[93]	giv|giv[93]	coref|coref	26-28[0_93]|26-28[0_93]
11-46	1910-1917	disease	abstract[93]	giv[93]	_	_
11-47	1918-1919	.	_	_	_	_

#Text=One of the central questions in the search for therapeutic targets for the treatment of flaviviral neurological syndromes is whether these diseases are induced by virus-mediated cytolysis , immune-pathological responses to infection , or a combination of both .
12-1	1920-1923	One	abstract[94]	new[94]	_	_
12-2	1924-1926	of	abstract[94]	new[94]	_	_
12-3	1927-1930	the	abstract[94]|abstract[95]	new[94]|new[95]	_	_
12-4	1931-1938	central	abstract[94]|abstract[95]	new[94]|new[95]	_	_
12-5	1939-1948	questions	abstract[94]|abstract[95]	new[94]|new[95]	_	_
12-6	1949-1951	in	abstract[94]|abstract[95]	new[94]|new[95]	_	_
12-7	1952-1955	the	abstract[94]|abstract[95]|event[96]	new[94]|new[95]|new[96]	_	_
12-8	1956-1962	search	abstract[94]|abstract[95]|event[96]	new[94]|new[95]|new[96]	_	_
12-9	1963-1966	for	abstract[94]|abstract[95]|event[96]	new[94]|new[95]|new[96]	_	_
12-10	1967-1978	therapeutic	abstract[94]|abstract[95]|event[96]|abstract[97]	new[94]|new[95]|new[96]|new[97]	coref	16-32[167_97]
12-11	1979-1986	targets	abstract[94]|abstract[95]|event[96]|abstract[97]	new[94]|new[95]|new[96]|new[97]	_	_
12-12	1987-1990	for	abstract[94]|abstract[95]|event[96]|abstract[97]	new[94]|new[95]|new[96]|new[97]	_	_
12-13	1991-1994	the	abstract[94]|abstract[95]|event[96]|abstract[97]|abstract[98]	new[94]|new[95]|new[96]|new[97]|new[98]	_	_
12-14	1995-2004	treatment	abstract[94]|abstract[95]|event[96]|abstract[97]|abstract[98]	new[94]|new[95]|new[96]|new[97]|new[98]	_	_
12-15	2005-2007	of	abstract[94]|abstract[95]|event[96]|abstract[97]|abstract[98]	new[94]|new[95]|new[96]|new[97]|new[98]	_	_
12-16	2008-2018	flaviviral	abstract[94]|abstract[95]|event[96]|abstract[97]|abstract[98]|abstract[99]	new[94]|new[95]|new[96]|new[97]|new[98]|giv[99]	_	_
12-17	2019-2031	neurological	abstract[94]|abstract[95]|event[96]|abstract[97]|abstract[98]|abstract[99]	new[94]|new[95]|new[96]|new[97]|new[98]|giv[99]	_	_
12-18	2032-2041	syndromes	abstract[94]|abstract[95]|event[96]|abstract[97]|abstract[98]|abstract[99]	new[94]|new[95]|new[96]|new[97]|new[98]|giv[99]	_	_
12-19	2042-2044	is	_	_	_	_
12-20	2045-2052	whether	_	_	_	_
12-21	2053-2058	these	abstract[100]	giv[100]	coref	13-45[121_100]
12-22	2059-2067	diseases	abstract[100]	giv[100]	_	_
12-23	2068-2071	are	_	_	_	_
12-24	2072-2079	induced	_	_	_	_
12-25	2080-2082	by	_	_	_	_
12-26	2083-2097	virus-mediated	abstract[101]	new[101]	_	_
12-27	2098-2107	cytolysis	abstract[101]	new[101]	_	_
12-28	2108-2109	,	_	_	_	_
12-29	2110-2129	immune-pathological	abstract[102]	new[102]	coref	13-38[120_102]
12-30	2130-2139	responses	abstract[102]	new[102]	_	_
12-31	2140-2142	to	abstract[102]	new[102]	_	_
12-32	2143-2152	infection	abstract[102]|abstract	new[102]|giv	coref	13-12[110_0]
12-33	2153-2154	,	_	_	_	_
12-34	2155-2157	or	_	_	_	_
12-35	2158-2159	a	abstract[104]	new[104]	_	_
12-36	2160-2171	combination	abstract[104]	new[104]	_	_
12-37	2172-2174	of	abstract[104]	new[104]	_	_
12-38	2175-2179	both	abstract[104]	new[104]	_	_
12-39	2180-2181	.	_	_	_	_

#Text=Animal models have permitted temporal analysis of the progressive dissemination of virus infection within the CNS and identification of cells targeted by viral infection , have revealed important details regarding host factors that restrict viral replication and the innate and adaptive immune responses to viral infections , and have been fundamental for vaccine development .
13-1	2182-2188	Animal	person|abstract[106]	new|new[106]	coref|coref	15-29[147_106]|15-29[147_106]
13-2	2189-2195	models	abstract[106]	new[106]	_	_
13-3	2196-2200	have	_	_	_	_
13-4	2201-2210	permitted	_	_	_	_
13-5	2211-2219	temporal	abstract[107]	new[107]	_	_
13-6	2220-2228	analysis	abstract[107]	new[107]	_	_
13-7	2229-2231	of	abstract[107]	new[107]	_	_
13-8	2232-2235	the	abstract[107]|abstract[108]	new[107]|new[108]	_	_
13-9	2236-2247	progressive	abstract[107]|abstract[108]	new[107]|new[108]	_	_
13-10	2248-2261	dissemination	abstract[107]|abstract[108]	new[107]|new[108]	_	_
13-11	2262-2264	of	abstract[107]|abstract[108]	new[107]|new[108]	_	_
13-12	2265-2270	virus	abstract[107]|abstract[108]|abstract|abstract[110]	new[107]|new[108]|giv|giv[110]	coref|coref|coref|coref	13-23[114_110]|16-17|13-23[114_110]|16-17
13-13	2271-2280	infection	abstract[107]|abstract[108]|abstract[110]	new[107]|new[108]|giv[110]	_	_
13-14	2281-2287	within	abstract[107]|abstract[108]|abstract[110]	new[107]|new[108]|giv[110]	_	_
13-15	2288-2291	the	abstract[107]|abstract[108]|abstract[110]|place[111]	new[107]|new[108]|giv[110]|new[111]	_	_
13-16	2292-2295	CNS	abstract[107]|abstract[108]|abstract[110]|place[111]	new[107]|new[108]|giv[110]|new[111]	_	_
13-17	2296-2299	and	abstract[107]|abstract[108]|abstract[110]	new[107]|new[108]|giv[110]	_	_
13-18	2300-2314	identification	abstract[107]|abstract[108]|abstract[110]|abstract[112]	new[107]|new[108]|giv[110]|new[112]	_	_
13-19	2315-2317	of	abstract[107]|abstract[108]|abstract[110]|abstract[112]	new[107]|new[108]|giv[110]|new[112]	_	_
13-20	2318-2323	cells	abstract[107]|abstract[108]|abstract[110]|abstract[112]|object	new[107]|new[108]|giv[110]|new[112]|new	coref	14-8[129_0]
13-21	2324-2332	targeted	_	_	_	_
13-22	2333-2335	by	_	_	_	_
13-23	2336-2341	viral	abstract[114]	giv[114]	coref	16-19[165_114]
13-24	2342-2351	infection	abstract[114]	giv[114]	_	_
13-25	2352-2353	,	_	_	_	_
13-26	2354-2358	have	_	_	_	_
13-27	2359-2367	revealed	_	_	_	_
13-28	2368-2377	important	abstract[115]	new[115]	_	_
13-29	2378-2385	details	abstract[115]	new[115]	_	_
13-30	2386-2395	regarding	_	_	_	_
13-31	2396-2400	host	abstract[116]	new[116]	_	_
13-32	2401-2408	factors	abstract[116]	new[116]	_	_
13-33	2409-2413	that	_	_	_	_
13-34	2414-2422	restrict	_	_	_	_
13-35	2423-2428	viral	abstract|abstract[118]	new|new[118]	coref|coref|coref|coref	20-30|22-13[0_118]|20-30|22-13[0_118]
13-36	2429-2440	replication	abstract[118]	new[118]	_	_
13-37	2441-2444	and	_	_	_	_
13-38	2445-2448	the	abstract[120]	giv[120]	coref	22-45[253_120]
13-39	2449-2455	innate	abstract[120]	giv[120]	_	_
13-40	2456-2459	and	abstract[120]	giv[120]	_	_
13-41	2460-2468	adaptive	abstract[120]	giv[120]	_	_
13-42	2469-2475	immune	abstract|abstract[120]	new|giv[120]	coref	19-5
13-43	2476-2485	responses	abstract[120]	giv[120]	_	_
13-44	2486-2488	to	abstract[120]	giv[120]	_	_
13-45	2489-2494	viral	abstract[120]|abstract[121]	giv[120]|giv[121]	coref	14-23[133_121]
13-46	2495-2505	infections	abstract[120]|abstract[121]	giv[120]|giv[121]	_	_
13-47	2506-2507	,	_	_	_	_
13-48	2508-2511	and	_	_	_	_
13-49	2512-2516	have	_	_	_	_
13-50	2517-2521	been	_	_	_	_
13-51	2522-2533	fundamental	_	_	_	_
13-52	2534-2537	for	_	_	_	_
13-53	2538-2545	vaccine	substance|abstract[123]	new|new[123]	coref|coref	15-59[157_123]|15-59[157_123]
13-54	2546-2557	development	abstract[123]	new[123]	_	_
13-55	2558-2559	.	_	_	_	_

#Text=Breakthroughs on cell reprogramming and generation of human induced pluripotent stem cells ( hiPSCs ) have revolutionized approaches to the study of human diseases . iPSCs are generated directly from adult differentiated cells that are reprogrammed back into an embryonic-like pluripotent state by introducing genes important for maintaining the essential properties of embryonic stem cells .
14-1	2560-2573	Breakthroughs	abstract[124]	new[124]	_	_
14-2	2574-2576	on	abstract[124]	new[124]	_	_
14-3	2577-2581	cell	abstract[124]|place|abstract[126]	new[124]|new|new[126]	coref|coref	17-29|17-29
14-4	2582-2595	reprogramming	abstract[124]|abstract[126]	new[124]|new[126]	_	_
14-5	2596-2599	and	abstract[124]	new[124]	_	_
14-6	2600-2610	generation	abstract[124]|abstract[127]	new[124]|new[127]	_	_
14-7	2611-2613	of	abstract[124]|abstract[127]	new[124]|new[127]	_	_
14-8	2614-2619	human	abstract[124]|abstract[127]|object[129]	new[124]|new[127]|giv[129]	appos	14-14[0_129]
14-9	2620-2627	induced	abstract[124]|abstract[127]|object[129]	new[124]|new[127]|giv[129]	_	_
14-10	2628-2639	pluripotent	abstract[124]|abstract[127]|object[129]	new[124]|new[127]|giv[129]	_	_
14-11	2640-2644	stem	abstract[124]|abstract[127]|plant|object[129]	new[124]|new[127]|new|giv[129]	coref	21-17
14-12	2645-2650	cells	abstract[124]|abstract[127]|object[129]	new[124]|new[127]|giv[129]	_	_
14-13	2651-2652	(	_	_	_	_
14-14	2653-2659	hiPSCs	object	giv	coref	14-31[135_0]
14-15	2660-2661	)	_	_	_	_
14-16	2662-2666	have	_	_	_	_
14-17	2667-2681	revolutionized	_	_	_	_
14-18	2682-2692	approaches	abstract[131]	new[131]	_	_
14-19	2693-2695	to	abstract[131]	new[131]	_	_
14-20	2696-2699	the	abstract[131]|abstract[132]	new[131]|new[132]	coref	22-2[236_132]
14-21	2700-2705	study	abstract[131]|abstract[132]	new[131]|new[132]	_	_
14-22	2706-2708	of	abstract[131]|abstract[132]	new[131]|new[132]	_	_
14-23	2709-2714	human	abstract[131]|abstract[132]|abstract[133]	new[131]|new[132]|giv[133]	coref	15-38[150_133]
14-24	2715-2723	diseases	abstract[131]|abstract[132]|abstract[133]	new[131]|new[132]|giv[133]	_	_
14-25	2724-2725	.	_	_	_	_
14-26	2726-2731	iPSCs	abstract	new	_	_
14-27	2732-2735	are	_	_	_	_
14-28	2736-2745	generated	_	_	_	_
14-29	2746-2754	directly	_	_	_	_
14-30	2755-2759	from	_	_	_	_
14-31	2760-2765	adult	object[135]	giv[135]	coref	14-53[140_135]
14-32	2766-2780	differentiated	object[135]	giv[135]	_	_
14-33	2781-2786	cells	object[135]	giv[135]	_	_
14-34	2787-2791	that	_	_	_	_
14-35	2792-2795	are	_	_	_	_
14-36	2796-2808	reprogrammed	_	_	_	_
14-37	2809-2813	back	_	_	_	_
14-38	2814-2818	into	_	_	_	_
14-39	2819-2821	an	abstract[137]	new[137]	_	_
14-40	2822-2836	embryonic-like	abstract[137]	new[137]	_	_
14-41	2837-2848	pluripotent	abstract|abstract[137]	new|new[137]	_	_
14-42	2849-2854	state	abstract[137]	new[137]	_	_
14-43	2855-2857	by	_	_	_	_
14-44	2858-2869	introducing	_	_	_	_
14-45	2870-2875	genes	abstract[138]	new[138]	coref	20-39[216_138]
14-46	2876-2885	important	abstract[138]	new[138]	_	_
14-47	2886-2889	for	_	_	_	_
14-48	2890-2901	maintaining	_	_	_	_
14-49	2902-2905	the	abstract[139]	new[139]	_	_
14-50	2906-2915	essential	abstract[139]	new[139]	_	_
14-51	2916-2926	properties	abstract[139]	new[139]	_	_
14-52	2927-2929	of	abstract[139]	new[139]	_	_
14-53	2930-2939	embryonic	abstract[139]|object[140]	new[139]|giv[140]	coref	15-3[142_140]
14-54	2940-2944	stem	abstract[139]|object[140]	new[139]|giv[140]	_	_
14-55	2945-2950	cells	abstract[139]|object[140]	new[139]|giv[140]	_	_
14-56	2951-2952	.	_	_	_	_

#Text=Generation of hiPSCs and their differentiation into a variety of cells and organoids have allow to set up versatile , non-invasive , ethically sustainable , cruelty-free , and patient-specific models for the investigation of the mechanisms of human diseases , including viral infections and host – pathogen interactions , for the discovery of new drugs , and for the development of personalized therapies .
15-1	2953-2963	Generation	abstract[141]	new[141]	_	_
15-2	2964-2966	of	abstract[141]	new[141]	_	_
15-3	2967-2973	hiPSCs	abstract[141]|object[142]	new[141]|giv[142]	coref	16-1[160_142]
15-4	2974-2977	and	abstract[141]|object[142]	new[141]|giv[142]	_	_
15-5	2978-2983	their	abstract[141]|object[142]|abstract[143]	new[141]|giv[142]|new[143]	coref	17-29[180_143]
15-6	2984-2999	differentiation	abstract[141]|object[142]|abstract[143]	new[141]|giv[142]|new[143]	_	_
15-7	3000-3004	into	abstract[141]|object[142]|abstract[143]	new[141]|giv[142]|new[143]	_	_
15-8	3005-3006	a	abstract[141]|object[142]|abstract[143]|object[144]	new[141]|giv[142]|new[143]|new[144]	_	_
15-9	3007-3014	variety	abstract[141]|object[142]|abstract[143]|object[144]	new[141]|giv[142]|new[143]|new[144]	_	_
15-10	3015-3017	of	abstract[141]|object[142]|abstract[143]|object[144]	new[141]|giv[142]|new[143]|new[144]	_	_
15-11	3018-3023	cells	abstract[141]|object[142]|abstract[143]|object[144]	new[141]|giv[142]|new[143]|new[144]	_	_
15-12	3024-3027	and	abstract[141]|object[142]|abstract[143]|object[144]	new[141]|giv[142]|new[143]|new[144]	_	_
15-13	3028-3037	organoids	abstract[141]|object[142]|abstract[143]|object[144]|abstract	new[141]|giv[142]|new[143]|new[144]|new	coref	16-6[161_0]
15-14	3038-3042	have	_	_	_	_
15-15	3043-3048	allow	_	_	_	_
15-16	3049-3051	to	_	_	_	_
15-17	3052-3055	set	_	_	_	_
15-18	3056-3058	up	_	_	_	_
15-19	3059-3068	versatile	_	_	_	_
15-20	3069-3070	,	_	_	_	_
15-21	3071-3083	non-invasive	_	_	_	_
15-22	3084-3085	,	_	_	_	_
15-23	3086-3095	ethically	_	_	_	_
15-24	3096-3107	sustainable	_	_	_	_
15-25	3108-3109	,	_	_	_	_
15-26	3110-3122	cruelty-free	abstract	new	_	_
15-27	3123-3124	,	_	_	_	_
15-28	3125-3128	and	_	_	_	_
15-29	3129-3145	patient-specific	abstract[147]	giv[147]	coref	26-6[283_147]
15-30	3146-3152	models	abstract[147]	giv[147]	_	_
15-31	3153-3156	for	abstract[147]	giv[147]	_	_
15-32	3157-3160	the	abstract[147]|abstract[148]	giv[147]|new[148]	coref	19-8[202_148]
15-33	3161-3174	investigation	abstract[147]|abstract[148]	giv[147]|new[148]	_	_
15-34	3175-3177	of	abstract[147]|abstract[148]	giv[147]|new[148]	_	_
15-35	3178-3181	the	abstract[147]|abstract[148]|abstract[149]	giv[147]|new[148]|new[149]	_	_
15-36	3182-3192	mechanisms	abstract[147]|abstract[148]|abstract[149]	giv[147]|new[148]|new[149]	_	_
15-37	3193-3195	of	abstract[147]|abstract[148]|abstract[149]	giv[147]|new[148]|new[149]	_	_
15-38	3196-3201	human	abstract[147]|abstract[148]|abstract[149]|abstract[150]	giv[147]|new[148]|new[149]|giv[150]	coref	15-42[151_150]
15-39	3202-3210	diseases	abstract[147]|abstract[148]|abstract[149]|abstract[150]	giv[147]|new[148]|new[149]|giv[150]	_	_
15-40	3211-3212	,	abstract[147]|abstract[148]|abstract[149]	giv[147]|new[148]|new[149]	_	_
15-41	3213-3222	including	abstract[147]|abstract[148]|abstract[149]	giv[147]|new[148]|new[149]	_	_
15-42	3223-3228	viral	abstract[147]|abstract[148]|abstract[149]|abstract[151]	giv[147]|new[148]|new[149]|giv[151]	_	_
15-43	3229-3239	infections	abstract[147]|abstract[148]|abstract[149]|abstract[151]	giv[147]|new[148]|new[149]|giv[151]	_	_
15-44	3240-3243	and	abstract[147]|abstract[148]|abstract[149]|abstract[151]	giv[147]|new[148]|new[149]|giv[151]	_	_
15-45	3244-3248	host	abstract[147]|abstract[148]|abstract[149]|abstract[151]|person	giv[147]|new[148]|new[149]|giv[151]|new	coref	22-45
15-46	3249-3250	–	abstract[147]|abstract[148]|abstract[149]|abstract[151]	giv[147]|new[148]|new[149]|giv[151]	_	_
15-47	3251-3259	pathogen	abstract[147]|abstract[148]|abstract[149]|abstract[151]|abstract|abstract[154]	giv[147]|new[148]|new[149]|giv[151]|new|new[154]	_	_
15-48	3260-3272	interactions	abstract[147]|abstract[148]|abstract[149]|abstract[151]|abstract[154]	giv[147]|new[148]|new[149]|giv[151]|new[154]	_	_
15-49	3273-3274	,	abstract[147]|abstract[148]|abstract[149]|abstract[151]|abstract[154]	giv[147]|new[148]|new[149]|giv[151]|new[154]	_	_
15-50	3275-3278	for	abstract[147]|abstract[148]|abstract[149]|abstract[151]|abstract[154]	giv[147]|new[148]|new[149]|giv[151]|new[154]	_	_
15-51	3279-3282	the	abstract[147]|abstract[148]|abstract[149]|abstract[151]|abstract[154]|abstract[155]	giv[147]|new[148]|new[149]|giv[151]|new[154]|new[155]	_	_
15-52	3283-3292	discovery	abstract[147]|abstract[148]|abstract[149]|abstract[151]|abstract[154]|abstract[155]	giv[147]|new[148]|new[149]|giv[151]|new[154]|new[155]	_	_
15-53	3293-3295	of	abstract[147]|abstract[148]|abstract[149]|abstract[151]|abstract[154]|abstract[155]	giv[147]|new[148]|new[149]|giv[151]|new[154]|new[155]	_	_
15-54	3296-3299	new	abstract[147]|abstract[148]|abstract[149]|abstract[151]|abstract[154]|abstract[155]|object[156]	giv[147]|new[148]|new[149]|giv[151]|new[154]|new[155]|new[156]	_	_
15-55	3300-3305	drugs	abstract[147]|abstract[148]|abstract[149]|abstract[151]|abstract[154]|abstract[155]|object[156]	giv[147]|new[148]|new[149]|giv[151]|new[154]|new[155]|new[156]	_	_
15-56	3306-3307	,	_	_	_	_
15-57	3308-3311	and	_	_	_	_
15-58	3312-3315	for	_	_	_	_
15-59	3316-3319	the	abstract[157]	giv[157]	coref	18-11[190_157]
15-60	3320-3331	development	abstract[157]	giv[157]	_	_
15-61	3332-3334	of	abstract[157]	giv[157]	_	_
15-62	3335-3347	personalized	abstract[157]|abstract[158]	giv[157]|new[158]	_	_
15-63	3348-3357	therapies	abstract[157]|abstract[158]	giv[157]|new[158]	_	_
15-64	3358-3359	.	_	_	_	_

#Text=Human iPSC-derived neural cells and brain organoids have been extensively used to investigate the mechanisms of ZIKV and other flavivirus infection and pathogenesis and have been used as platforms to discover therapeutic targets and to test antiviral compounds .
16-1	3360-3365	Human	object[160]	giv[160]	coref	17-4[0_160]
16-2	3366-3378	iPSC-derived	substance|object[160]	new|giv[160]	coref	18-2
16-3	3379-3385	neural	object[160]	giv[160]	_	_
16-4	3386-3391	cells	object[160]	giv[160]	_	_
16-5	3392-3395	and	object[160]	giv[160]	_	_
16-6	3396-3401	brain	object[160]|abstract[161]	giv[160]|giv[161]	coref	18-1[187_161]
16-7	3402-3411	organoids	object[160]|abstract[161]	giv[160]|giv[161]	_	_
16-8	3412-3416	have	_	_	_	_
16-9	3417-3421	been	_	_	_	_
16-10	3422-3433	extensively	_	_	_	_
16-11	3434-3438	used	_	_	_	_
16-12	3439-3441	to	_	_	_	_
16-13	3442-3453	investigate	_	_	_	_
16-14	3454-3457	the	abstract[162]	new[162]	coref	19-10[203_162]
16-15	3458-3468	mechanisms	abstract[162]	new[162]	_	_
16-16	3469-3471	of	abstract[162]	new[162]	_	_
16-17	3472-3476	ZIKV	abstract[162]|abstract	new[162]|giv	coref	17-15[174_0]
16-18	3477-3480	and	abstract[162]	new[162]	_	_
16-19	3481-3486	other	abstract[162]|abstract[165]	new[162]|giv[165]	coref	17-26[178_165]
16-20	3487-3497	flavivirus	abstract[162]|object|abstract[165]	new[162]|giv|giv[165]	_	_
16-21	3498-3507	infection	abstract[162]|abstract[165]	new[162]|giv[165]	_	_
16-22	3508-3511	and	abstract[162]	new[162]	_	_
16-23	3512-3524	pathogenesis	abstract[162]|abstract	new[162]|new	_	_
16-24	3525-3528	and	_	_	_	_
16-25	3529-3533	have	_	_	_	_
16-26	3534-3538	been	_	_	_	_
16-27	3539-3543	used	_	_	_	_
16-28	3544-3546	as	_	_	_	_
16-29	3547-3556	platforms	_	_	_	_
16-30	3557-3559	to	_	_	_	_
16-31	3560-3568	discover	_	_	_	_
16-32	3569-3580	therapeutic	abstract[167]	giv[167]	_	_
16-33	3581-3588	targets	abstract[167]	giv[167]	_	_
16-34	3589-3592	and	_	_	_	_
16-35	3593-3595	to	_	_	_	_
16-36	3596-3600	test	_	_	_	_
16-37	3601-3610	antiviral	object[168]	new[168]	_	_
16-38	3611-3620	compounds	object[168]	new[168]	_	_
16-39	3621-3622	.	_	_	_	_

#Text=Initial studies with hiPSCs studies were crucial to provide evidence of the tropism of ZIKV for human cortical neural progenitor cells and to demonstrate that ZIKV infection impairs cell differentiation and induces apoptosis , supporting the causative role of ZIKV in fetal microcephaly .
17-1	3623-3630	Initial	abstract[169]	new[169]	_	_
17-2	3631-3638	studies	abstract[169]	new[169]	_	_
17-3	3639-3643	with	abstract[169]	new[169]	_	_
17-4	3644-3650	hiPSCs	abstract[169]|object|abstract[171]	new[169]|giv|new[171]	coref|coref	17-17[176_0]|17-17[176_0]
17-5	3651-3658	studies	abstract[169]|abstract[171]	new[169]|new[171]	_	_
17-6	3659-3663	were	_	_	_	_
17-7	3664-3671	crucial	_	_	_	_
17-8	3672-3674	to	_	_	_	_
17-9	3675-3682	provide	_	_	_	_
17-10	3683-3691	evidence	abstract[172]	new[172]	_	_
17-11	3692-3694	of	abstract[172]	new[172]	_	_
17-12	3695-3698	the	abstract[172]|abstract[173]	new[172]|new[173]	coref	21-13[227_173]
17-13	3699-3706	tropism	abstract[172]|abstract[173]	new[172]|new[173]	_	_
17-14	3707-3709	of	abstract[172]|abstract[173]	new[172]|new[173]	_	_
17-15	3710-3714	ZIKV	abstract[172]|abstract[173]|abstract[174]	new[172]|new[173]|giv[174]	coref	17-26[0_174]
17-16	3715-3718	for	abstract[172]|abstract[173]|abstract[174]	new[172]|new[173]|giv[174]	_	_
17-17	3719-3724	human	abstract[172]|abstract[173]|abstract[174]|object[176]	new[172]|new[173]|giv[174]|giv[176]	coref	18-23[194_176]
17-18	3725-3733	cortical	abstract[172]|abstract[173]|abstract[174]|object[176]	new[172]|new[173]|giv[174]|giv[176]	_	_
17-19	3734-3740	neural	abstract[172]|abstract[173]|abstract[174]|object[176]	new[172]|new[173]|giv[174]|giv[176]	_	_
17-20	3741-3751	progenitor	abstract[172]|abstract[173]|abstract[174]|object|object[176]	new[172]|new[173]|giv[174]|new|giv[176]	_	_
17-21	3752-3757	cells	abstract[172]|abstract[173]|abstract[174]|object[176]	new[172]|new[173]|giv[174]|giv[176]	_	_
17-22	3758-3761	and	_	_	_	_
17-23	3762-3764	to	_	_	_	_
17-24	3765-3776	demonstrate	_	_	_	_
17-25	3777-3781	that	_	_	_	_
17-26	3782-3786	ZIKV	object|abstract[178]	giv|giv[178]	coref|coref|coref|coref	17-40[183_0]|20-30[214_178]|17-40[183_0]|20-30[214_178]
17-27	3787-3796	infection	abstract[178]	giv[178]	_	_
17-28	3797-3804	impairs	_	_	_	_
17-29	3805-3809	cell	place|abstract[180]	giv|giv[180]	coref|coref|coref|coref	18-37|20-19[0_180]|18-37|20-19[0_180]
17-30	3810-3825	differentiation	abstract[180]	giv[180]	_	_
17-31	3826-3829	and	_	_	_	_
17-32	3830-3837	induces	_	_	_	_
17-33	3838-3847	apoptosis	event	new	_	_
17-34	3848-3849	,	_	_	_	_
17-35	3850-3860	supporting	_	_	_	_
17-36	3861-3864	the	abstract[182]	new[182]	_	_
17-37	3865-3874	causative	abstract[182]	new[182]	_	_
17-38	3875-3879	role	abstract[182]	new[182]	_	_
17-39	3880-3882	of	abstract[182]	new[182]	_	_
17-40	3883-3887	ZIKV	abstract[182]|abstract[183]	new[182]|giv[183]	coref	18-20[0_183]
17-41	3888-3890	in	abstract[182]|abstract[183]	new[182]|giv[183]	_	_
17-42	3891-3896	fetal	abstract[182]|abstract[183]|object[184]	new[182]|giv[183]|new[184]	_	_
17-43	3897-3909	microcephaly	abstract[182]|abstract[183]|object[184]	new[182]|giv[183]|new[184]	_	_
17-44	3910-3911	.	_	_	_	_

#Text=Human iPSC-derived brain organoids , which are 3D structures mimicking endogenous human brain development and organization , showed that ZIKV preferentially infects radial glia cells as compared to intermediate progenitors or immature neurons , leading to cell death .
18-1	3912-3917	Human	abstract[187]	giv[187]	_	_
18-2	3918-3930	iPSC-derived	abstract|abstract[187]	giv|giv[187]	_	_
18-3	3931-3936	brain	object|abstract[187]	new|giv[187]	coref	18-13
18-4	3937-3946	organoids	abstract[187]	giv[187]	_	_
18-5	3947-3948	,	_	_	_	_
18-6	3949-3954	which	_	_	_	_
18-7	3955-3958	are	_	_	_	_
18-8	3959-3961	3D	object[188]	new[188]	_	_
18-9	3962-3972	structures	object[188]	new[188]	_	_
18-10	3973-3982	mimicking	_	_	_	_
18-11	3983-3993	endogenous	abstract[190]	giv[190]	_	_
18-12	3994-3999	human	abstract[190]	giv[190]	_	_
18-13	4000-4005	brain	object|abstract[190]	giv|giv[190]	_	_
18-14	4006-4017	development	abstract[190]	giv[190]	_	_
18-15	4018-4021	and	_	_	_	_
18-16	4022-4034	organization	abstract	new	_	_
18-17	4035-4036	,	_	_	_	_
18-18	4037-4043	showed	_	_	_	_
18-19	4044-4048	that	_	_	_	_
18-20	4049-4053	ZIKV	abstract	giv	coref	19-13
18-21	4054-4068	preferentially	_	_	_	_
18-22	4069-4076	infects	_	_	_	_
18-23	4077-4083	radial	object[194]	giv[194]	coref	20-23[212_194]
18-24	4084-4088	glia	place|object[194]	new|giv[194]	_	_
18-25	4089-4094	cells	object[194]	giv[194]	_	_
18-26	4095-4097	as	_	_	_	_
18-27	4098-4106	compared	_	_	_	_
18-28	4107-4109	to	_	_	_	_
18-29	4110-4122	intermediate	object[195]	new[195]	_	_
18-30	4123-4134	progenitors	object[195]	new[195]	_	_
18-31	4135-4137	or	_	_	_	_
18-32	4138-4146	immature	object[196]	new[196]	coref	22-35[249_196]
18-33	4147-4154	neurons	object[196]	new[196]	_	_
18-34	4155-4156	,	_	_	_	_
18-35	4157-4164	leading	_	_	_	_
18-36	4165-4167	to	_	_	_	_
18-37	4168-4172	cell	object|event[198]	giv|new[198]	coref|coref|coref|coref	20-18|24-28[271_198]|20-18|24-28[271_198]
18-38	4173-4178	death	event[198]	new[198]	_	_
18-39	4179-4180	.	_	_	_	_

#Text=Activation of TLR3-mediated innate immune response was one of the mechanisms involved ZIKV deleterious effects on neurogenesis .
19-1	4181-4191	Activation	event[199]	new[199]	_	_
19-2	4192-4194	of	event[199]	new[199]	_	_
19-3	4195-4208	TLR3-mediated	event[199]|abstract[201]	new[199]|new[201]	coref	25-23[278_201]
19-4	4209-4215	innate	event[199]|abstract[201]	new[199]|new[201]	_	_
19-5	4216-4222	immune	event[199]|abstract|abstract[201]	new[199]|giv|new[201]	coref	25-23
19-6	4223-4231	response	event[199]|abstract[201]	new[199]|new[201]	_	_
19-7	4232-4235	was	_	_	_	_
19-8	4236-4239	one	abstract[202]	giv[202]	_	_
19-9	4240-4242	of	abstract[202]	giv[202]	_	_
19-10	4243-4246	the	abstract[202]|abstract[203]	giv[202]|giv[203]	coref	26-14[285_203]
19-11	4247-4257	mechanisms	abstract[202]|abstract[203]	giv[202]|giv[203]	_	_
19-12	4258-4266	involved	_	_	_	_
19-13	4267-4271	ZIKV	abstract|abstract[205]	giv|new[205]	coref|coref	21-9|21-9
19-14	4272-4283	deleterious	abstract[205]	new[205]	_	_
19-15	4284-4291	effects	abstract[205]	new[205]	_	_
19-16	4292-4294	on	abstract[205]	new[205]	_	_
19-17	4295-4307	neurogenesis	abstract[205]|abstract	new[205]|new	_	_
19-18	4308-4309	.	_	_	_	_

#Text=In addition , the ability of viruses to infect and replicate was found to be dependent on cell differentiation status , since stem cells appear to be refractory to viral infection probably due to constitutive high-level expression of interferon-stimulated genes ( ISGs ) , while cell susceptibility to viral infection increases in differentiated cells .
20-1	4310-4312	In	_	_	_	_
20-2	4313-4321	addition	_	_	_	_
20-3	4322-4323	,	_	_	_	_
20-4	4324-4327	the	abstract[207]	new[207]	_	_
20-5	4328-4335	ability	abstract[207]	new[207]	_	_
20-6	4336-4338	of	abstract[207]	new[207]	_	_
20-7	4339-4346	viruses	abstract[207]|object	new[207]|giv	_	_
20-8	4347-4349	to	_	_	_	_
20-9	4350-4356	infect	_	_	_	_
20-10	4357-4360	and	_	_	_	_
20-11	4361-4370	replicate	_	_	_	_
20-12	4371-4374	was	_	_	_	_
20-13	4375-4380	found	_	_	_	_
20-14	4381-4383	to	_	_	_	_
20-15	4384-4386	be	_	_	_	_
20-16	4387-4396	dependent	_	_	_	_
20-17	4397-4399	on	_	_	_	_
20-18	4400-4404	cell	place|abstract[211]	giv|new[211]	coref|coref	20-46|20-46
20-19	4405-4420	differentiation	abstract|abstract[211]	giv|new[211]	coref	23-16[260_0]
20-20	4421-4427	status	abstract[211]	new[211]	_	_
20-21	4428-4429	,	_	_	_	_
20-22	4430-4435	since	_	_	_	_
20-23	4436-4440	stem	object[212]	giv[212]	coref	20-53[222_212]
20-24	4441-4446	cells	object[212]	giv[212]	_	_
20-25	4447-4453	appear	_	_	_	_
20-26	4454-4456	to	_	_	_	_
20-27	4457-4459	be	_	_	_	_
20-28	4460-4470	refractory	_	_	_	_
20-29	4471-4473	to	_	_	_	_
20-30	4474-4479	viral	object|abstract[214]	giv|giv[214]	coref|coref|coref|coref	20-49|20-49[221_214]|20-49|20-49[221_214]
20-31	4480-4489	infection	abstract[214]	giv[214]	_	_
20-32	4490-4498	probably	_	_	_	_
20-33	4499-4502	due	_	_	_	_
20-34	4503-4505	to	_	_	_	_
20-35	4506-4518	constitutive	abstract[215]	new[215]	coref	25-21[280_215]
20-36	4519-4529	high-level	abstract[215]	new[215]	_	_
20-37	4530-4540	expression	abstract[215]	new[215]	_	_
20-38	4541-4543	of	abstract[215]	new[215]	_	_
20-39	4544-4565	interferon-stimulated	abstract[215]|abstract[216]	new[215]|giv[216]	_	_
20-40	4566-4571	genes	abstract[215]|abstract[216]	new[215]|giv[216]	_	_
20-41	4572-4573	(	_	_	_	_
20-42	4574-4578	ISGs	event	new	_	_
20-43	4579-4580	)	_	_	_	_
20-44	4581-4582	,	_	_	_	_
20-45	4583-4588	while	_	_	_	_
20-46	4589-4593	cell	place|event[219]	giv|new[219]	coref|coref	23-17|23-17
20-47	4594-4608	susceptibility	event[219]	new[219]	_	_
20-48	4609-4611	to	event[219]	new[219]	_	_
20-49	4612-4617	viral	event[219]|object|abstract[221]	new[219]|giv|giv[221]	coref|coref	22-42[251_221]|22-42[251_221]
20-50	4618-4627	infection	event[219]|abstract[221]	new[219]|giv[221]	_	_
20-51	4628-4637	increases	_	_	_	_
20-52	4638-4640	in	_	_	_	_
20-53	4641-4655	differentiated	object[222]	giv[222]	coref	21-16[229_222]
20-54	4656-4661	cells	object[222]	giv[222]	_	_
20-55	4662-4663	.	_	_	_	_

#Text=Comparisons with other flaviviruses — e. g. , DENV — showed that the tropism for neural stem cells was a distinguishing feature of ZIKV , but no extensive comparative analyses have been performed with typically neurotropic flaviviruses like WNV .
21-1	4664-4675	Comparisons	abstract[223]	new[223]	_	_
21-2	4676-4680	with	abstract[223]	new[223]	_	_
21-3	4681-4686	other	abstract[223]|abstract[224]	new[223]|giv[224]	appos	21-6[225_224]
21-4	4687-4699	flaviviruses	abstract[223]|abstract[224]	new[223]|giv[224]	_	_
21-5	4700-4701	—	_	_	_	_
21-6	4702-4704	e.	abstract[225]	giv[225]	coref	21-35[234_225]
21-7	4705-4707	g.	abstract[225]	giv[225]	_	_
21-8	4708-4709	,	abstract[225]	giv[225]	_	_
21-9	4710-4714	DENV	abstract[225]|abstract	giv[225]|giv	coref	21-24
21-10	4715-4716	—	_	_	_	_
21-11	4717-4723	showed	_	_	_	_
21-12	4724-4728	that	_	_	_	_
21-13	4729-4732	the	abstract[227]	giv[227]	coref	21-20[230_227]
21-14	4733-4740	tropism	abstract[227]	giv[227]	_	_
21-15	4741-4744	for	abstract[227]	giv[227]	_	_
21-16	4745-4751	neural	abstract[227]|object[229]	giv[227]|giv[229]	coref	22-25[0_229]
21-17	4752-4756	stem	abstract[227]|plant|object[229]	giv[227]|giv|giv[229]	coref	22-29
21-18	4757-4762	cells	abstract[227]|object[229]	giv[227]|giv[229]	_	_
21-19	4763-4766	was	_	_	_	_
21-20	4767-4768	a	abstract[230]	giv[230]	coref	22-10[0_230]
21-21	4769-4783	distinguishing	abstract[230]	giv[230]	_	_
21-22	4784-4791	feature	abstract[230]	giv[230]	_	_
21-23	4792-4794	of	abstract[230]	giv[230]	_	_
21-24	4795-4799	ZIKV	abstract[230]|abstract	giv[230]|giv	coref	22-16
21-25	4800-4801	,	_	_	_	_
21-26	4802-4805	but	_	_	_	_
21-27	4806-4808	no	abstract[232]	new[232]	_	_
21-28	4809-4818	extensive	abstract[232]	new[232]	_	_
21-29	4819-4830	comparative	abstract[232]	new[232]	_	_
21-30	4831-4839	analyses	abstract[232]	new[232]	_	_
21-31	4840-4844	have	_	_	_	_
21-32	4845-4849	been	_	_	_	_
21-33	4850-4859	performed	_	_	_	_
21-34	4860-4864	with	_	_	_	_
21-35	4865-4874	typically	object[234]	giv[234]	coref	25-6[273_234]
21-36	4875-4886	neurotropic	abstract|object[234]	giv|giv[234]	_	_
21-37	4887-4899	flaviviruses	object[234]	giv[234]	_	_
21-38	4900-4904	like	object[234]	giv[234]	_	_
21-39	4905-4908	WNV	object[234]|abstract	giv[234]|giv	coref	22-21
21-40	4909-4910	.	_	_	_	_

#Text=In this study , we investigated the infectivity , tropism , and replication kinetics of ZIKV , in comparison with WNV and DENV in hiPSCs , hiPSCs-derived neural stem cells ( NSCs ) and undifferentiated neurons , and the effect of viral infection on host innate antiviral responses .
22-1	4911-4913	In	_	_	_	_
22-2	4914-4918	this	abstract[236]	giv[236]	coref	24-4[263_236]
22-3	4919-4924	study	abstract[236]	giv[236]	_	_
22-4	4925-4926	,	_	_	_	_
22-5	4927-4929	we	person	acc	ana	23-4
22-6	4930-4942	investigated	_	_	_	_
22-7	4943-4946	the	abstract[238]	new[238]	_	_
22-8	4947-4958	infectivity	abstract[238]	new[238]	_	_
22-9	4959-4960	,	_	_	_	_
22-10	4961-4968	tropism	abstract	giv	_	_
22-11	4969-4970	,	_	_	_	_
22-12	4971-4974	and	_	_	_	_
22-13	4975-4986	replication	abstract|abstract[241]	giv|new[241]	_	_
22-14	4987-4995	kinetics	abstract[241]	new[241]	_	_
22-15	4996-4998	of	abstract[241]	new[241]	_	_
22-16	4999-5003	ZIKV	abstract[241]|abstract	new[241]|giv	coref	22-23[245_0]
22-17	5004-5005	,	abstract[241]	new[241]	_	_
22-18	5006-5008	in	abstract[241]	new[241]	_	_
22-19	5009-5019	comparison	abstract[241]|abstract[243]	new[241]|new[243]	_	_
22-20	5020-5024	with	abstract[241]|abstract[243]	new[241]|new[243]	_	_
22-21	5025-5028	WNV	abstract[241]|abstract[243]|abstract	new[241]|new[243]|giv	coref	24-17
22-22	5029-5032	and	abstract[241]|abstract[243]	new[241]|new[243]	_	_
22-23	5033-5037	DENV	abstract[241]|abstract[243]|abstract[245]	new[241]|new[243]|giv[245]	coref	23-9[0_245]
22-24	5038-5040	in	abstract[241]|abstract[243]|abstract[245]	new[241]|new[243]|giv[245]	_	_
22-25	5041-5047	hiPSCs	abstract[241]|abstract[243]|abstract[245]|object	new[241]|new[243]|giv[245]|giv	coref	22-27[248_0]
22-26	5048-5049	,	_	_	_	_
22-27	5050-5064	hiPSCs-derived	object[248]	giv[248]	coref	23-6[0_248]
22-28	5065-5071	neural	object[248]	giv[248]	_	_
22-29	5072-5076	stem	plant|object[248]	giv|giv[248]	_	_
22-30	5077-5082	cells	object[248]	giv[248]	_	_
22-31	5083-5084	(	object[248]	giv[248]	_	_
22-32	5085-5089	NSCs	object[248]	giv[248]	_	_
22-33	5090-5091	)	object[248]	giv[248]	_	_
22-34	5092-5095	and	_	_	_	_
22-35	5096-5112	undifferentiated	object[249]	giv[249]	coref	25-15[0_249]
22-36	5113-5120	neurons	object[249]	giv[249]	_	_
22-37	5121-5122	,	_	_	_	_
22-38	5123-5126	and	_	_	_	_
22-39	5127-5130	the	abstract[250]	new[250]	_	_
22-40	5131-5137	effect	abstract[250]	new[250]	_	_
22-41	5138-5140	of	abstract[250]	new[250]	_	_
22-42	5141-5146	viral	abstract[250]|abstract[251]	new[250]|giv[251]	coref	23-9[257_251]
22-43	5147-5156	infection	abstract[250]|abstract[251]	new[250]|giv[251]	_	_
22-44	5157-5159	on	abstract[250]|abstract[251]	new[250]|giv[251]	_	_
22-45	5160-5164	host	abstract[250]|abstract[251]|person|abstract[253]	new[250]|giv[251]|giv|giv[253]	_	_
22-46	5165-5171	innate	abstract[250]|abstract[251]|abstract[253]	new[250]|giv[251]|giv[253]	_	_
22-47	5172-5181	antiviral	abstract[250]|abstract[251]|abstract[253]	new[250]|giv[251]|giv[253]	_	_
22-48	5182-5191	responses	abstract[250]|abstract[251]|abstract[253]	new[250]|giv[251]|giv[253]	_	_
22-49	5192-5193	.	_	_	_	_

#Text=In addition , we exploited hiPSCs to model ZIKV infection in the embryo and during stem cell differentiation towards the neuronal lineage .
23-1	5194-5196	In	_	_	_	_
23-2	5197-5205	addition	_	_	_	_
23-3	5206-5207	,	_	_	_	_
23-4	5208-5210	we	person	giv	_	_
23-5	5211-5220	exploited	_	_	_	_
23-6	5221-5227	hiPSCs	object	giv	coref	24-20[268_0]
23-7	5228-5230	to	_	_	_	_
23-8	5231-5236	model	_	_	_	_
23-9	5237-5241	ZIKV	object|abstract[257]	giv|giv[257]	coref|coref|coref|coref	24-10|26-7[0_257]|24-10|26-7[0_257]
23-10	5242-5251	infection	abstract[257]	giv[257]	_	_
23-11	5252-5254	in	abstract[257]	giv[257]	_	_
23-12	5255-5258	the	abstract[257]|place[258]	giv[257]|new[258]	_	_
23-13	5259-5265	embryo	abstract[257]|place[258]	giv[257]|new[258]	_	_
23-14	5266-5269	and	_	_	_	_
23-15	5270-5276	during	_	_	_	_
23-16	5277-5281	stem	abstract[260]	giv[260]	_	_
23-17	5282-5286	cell	place|abstract[260]	giv|giv[260]	coref	24-29
23-18	5287-5302	differentiation	abstract[260]	giv[260]	_	_
23-19	5303-5310	towards	abstract[260]	giv[260]	_	_
23-20	5311-5314	the	abstract[260]|abstract[261]	giv[260]|new[261]	_	_
23-21	5315-5323	neuronal	abstract[260]|abstract[261]	giv[260]|new[261]	_	_
23-22	5324-5331	lineage	abstract[260]|abstract[261]	giv[260]|new[261]	_	_
23-23	5332-5333	.	_	_	_	_

#Text=The results of this study confirmed the tropism of ZIKV for NSCs , but showed that WNV replicated in these cells with much higher efficiency , inducing massive cell death .
24-1	5334-5337	The	abstract[262]	new[262]	_	_
24-2	5338-5345	results	abstract[262]	new[262]	_	_
24-3	5346-5348	of	abstract[262]	new[262]	_	_
24-4	5349-5353	this	abstract[262]|abstract[263]	new[262]|giv[263]	_	_
24-5	5354-5359	study	abstract[262]|abstract[263]	new[262]|giv[263]	_	_
24-6	5360-5369	confirmed	_	_	_	_
24-7	5370-5373	the	abstract[264]	new[264]	coref	26-19[286_264]
24-8	5374-5381	tropism	abstract[264]	new[264]	_	_
24-9	5382-5384	of	abstract[264]	new[264]	_	_
24-10	5385-5389	ZIKV	abstract[264]|abstract	new[264]|giv	_	_
24-11	5390-5393	for	_	_	_	_
24-12	5394-5398	NSCs	organization	new	_	_
24-13	5399-5400	,	_	_	_	_
24-14	5401-5404	but	_	_	_	_
24-15	5405-5411	showed	_	_	_	_
24-16	5412-5416	that	_	_	_	_
24-17	5417-5420	WNV	abstract	giv	_	_
24-18	5421-5431	replicated	_	_	_	_
24-19	5432-5434	in	_	_	_	_
24-20	5435-5440	these	object[268]	giv[268]	coref	25-11[274_268]
24-21	5441-5446	cells	object[268]	giv[268]	_	_
24-22	5447-5451	with	_	_	_	_
24-23	5452-5456	much	abstract[269]	new[269]	_	_
24-24	5457-5463	higher	abstract[269]	new[269]	_	_
24-25	5464-5474	efficiency	abstract[269]	new[269]	_	_
24-26	5475-5476	,	_	_	_	_
24-27	5477-5485	inducing	_	_	_	_
24-28	5486-5493	massive	event[271]	giv[271]	_	_
24-29	5494-5498	cell	place|event[271]	giv|giv[271]	_	_
24-30	5499-5504	death	event[271]	giv[271]	_	_
24-31	5505-5506	.	_	_	_	_

#Text=Although with lower efficiency , all flaviviruses could also infect pluripotent stem cells and neurons , inducing similar patterns of antiviral innate immune response gene expression .
25-1	5507-5515	Although	_	_	_	_
25-2	5516-5520	with	_	_	_	_
25-3	5521-5526	lower	abstract[272]	new[272]	_	_
25-4	5527-5537	efficiency	abstract[272]	new[272]	_	_
25-5	5538-5539	,	_	_	_	_
25-6	5540-5543	all	object[273]	giv[273]	_	_
25-7	5544-5556	flaviviruses	object[273]	giv[273]	_	_
25-8	5557-5562	could	_	_	_	_
25-9	5563-5567	also	_	_	_	_
25-10	5568-5574	infect	_	_	_	_
25-11	5575-5586	pluripotent	object[274]	giv[274]	_	_
25-12	5587-5591	stem	object[274]	giv[274]	_	_
25-13	5592-5597	cells	object[274]	giv[274]	_	_
25-14	5598-5601	and	object[274]	giv[274]	_	_
25-15	5602-5609	neurons	object[274]|object	giv[274]|giv	_	_
25-16	5610-5611	,	_	_	_	_
25-17	5612-5620	inducing	_	_	_	_
25-18	5621-5628	similar	abstract[276]	new[276]	_	_
25-19	5629-5637	patterns	abstract[276]	new[276]	_	_
25-20	5638-5640	of	abstract[276]	new[276]	_	_
25-21	5641-5650	antiviral	abstract[276]|abstract[280]	new[276]|giv[280]	_	_
25-22	5651-5657	innate	abstract[276]|abstract[280]	new[276]|giv[280]	_	_
25-23	5658-5664	immune	abstract[276]|abstract|abstract[278]|abstract[280]	new[276]|giv|giv[278]|giv[280]	_	_
25-24	5665-5673	response	abstract[276]|abstract[278]|abstract[280]	new[276]|giv[278]|giv[280]	_	_
25-25	5674-5678	gene	abstract[276]|abstract|abstract[280]	new[276]|new|giv[280]	_	_
25-26	5679-5689	expression	abstract[276]|abstract[280]	new[276]|giv[280]	_	_
25-27	5690-5691	.	_	_	_	_

#Text=While showing the usefulness of hiPSC-based infection models , these findings suggest that additional virus-specific mechanisms , beyond neural tropism , are responsible for the peculiarities of disease phenotype in humans .
26-1	5692-5697	While	_	_	_	_
26-2	5698-5705	showing	_	_	_	_
26-3	5706-5709	the	abstract[281]	new[281]	_	_
26-4	5710-5720	usefulness	abstract[281]	new[281]	_	_
26-5	5721-5723	of	abstract[281]	new[281]	_	_
26-6	5724-5735	hiPSC-based	abstract[281]|abstract[283]	new[281]|giv[283]	_	_
26-7	5736-5745	infection	abstract[281]|abstract|abstract[283]	new[281]|giv|giv[283]	_	_
26-8	5746-5752	models	abstract[281]|abstract[283]	new[281]|giv[283]	_	_
26-9	5753-5754	,	_	_	_	_
26-10	5755-5760	these	abstract[284]	new[284]	_	_
26-11	5761-5769	findings	abstract[284]	new[284]	_	_
26-12	5770-5777	suggest	_	_	_	_
26-13	5778-5782	that	_	_	_	_
26-14	5783-5793	additional	abstract[285]	giv[285]	_	_
26-15	5794-5808	virus-specific	abstract[285]	giv[285]	_	_
26-16	5809-5819	mechanisms	abstract[285]	giv[285]	_	_
26-17	5820-5821	,	abstract[285]	giv[285]	_	_
26-18	5822-5828	beyond	abstract[285]	giv[285]	_	_
26-19	5829-5835	neural	abstract[285]|abstract[286]	giv[285]|giv[286]	_	_
26-20	5836-5843	tropism	abstract[285]|abstract[286]	giv[285]|giv[286]	_	_
26-21	5844-5845	,	_	_	_	_
26-22	5846-5849	are	_	_	_	_
26-23	5850-5861	responsible	_	_	_	_
26-24	5862-5865	for	_	_	_	_
26-25	5866-5869	the	abstract[287]	new[287]	_	_
26-26	5870-5883	peculiarities	abstract[287]	new[287]	_	_
26-27	5884-5886	of	abstract[287]	new[287]	_	_
26-28	5887-5894	disease	abstract[287]|abstract|abstract[289]	new[287]|giv|new[289]	_	_
26-29	5895-5904	phenotype	abstract[287]|abstract[289]	new[287]|new[289]	_	_
26-30	5905-5907	in	abstract[287]|abstract[289]	new[287]|new[289]	_	_
26-31	5908-5914	humans	abstract[287]|abstract[289]|person	new[287]|new[289]|giv	_	_
26-32	5915-5916	.	_	_	_	_
